In a report issued on July 6, Andrew Fein from H.C. Wainwright reiterated a Buy rating on BELLUS Health (BLU – Research Report), with a price target of $28.00. The company’s shares closed last Wednesday at $2.97, close to its 52-week low of $2.52.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 14.6% and a 49.3% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Deciphera Pharmaceuticals.
BELLUS Health has an analyst consensus of Moderate Buy, with a price target consensus of $9.74, implying a 210.2% upside from current levels. In a report issued on July 6, Jefferies also maintained a Buy rating on the stock with a $6.00 price target.
The company has a one-year high of $12.03 and a one-year low of $2.52. Currently, BELLUS Health has an average volume of 2.71M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BELLUS Health, Inc. is a biopharmaceutical development company which engages in the research and development of novel therapeutics for the treatment of chronic cough and other hypersensitisation disorders. Its product, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.